Arbutus Biopharma
ABUS
51 hedge funds and large institutions have $61.1M invested in Arbutus Biopharma in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 49 → 51 (+2)
16% less call options, than puts
Call options by funds: $470K | Put options by funds: $560K
17% less capital invested
Capital invested by funds: $73.1M → $61.1M (-$12.1M)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.73M |
| 2 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
+$1.06M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$423K |
| 4 |
Morgan Stanley
New York
|
+$251K |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$896K |
| 2 |
Renaissance Technologies
New York
|
-$840K |
| 3 |
DCM
Dialectic Capital Management
Norwalk,
Connecticut
|
-$740K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$654K |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$516K |
ABUS Hedge Fund Activity: Q2 2016 in Review
51 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2016, worth a combined $61.1M — down 17% from $73.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ABUS positions and 6 closed out — a net gain of 2 holders — while 14 added to existing stakes and 17 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.73M. The largest seller was Millennium Management, cutting an estimated $896K.
- 51 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2016, up from 49 in Q1 2016.
- Funds reported $61.1M of Arbutus Biopharma stock for Q2 2016, down 17% quarter-over-quarter.
- 8 funds opened new Arbutus Biopharma positions in Q2 2016 and 6 closed out, a net change of +2 holders.
- The largest Arbutus Biopharma buyer in Q2 2016 was Armistice Capital, an estimated $1.73M added.
- The largest Arbutus Biopharma seller in Q2 2016 was Millennium Management, an estimated $896K sold.
Based on aggregated 13F filings for Q2 2016.